Literature DB >> 17019596

Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives.

P Achenbach1, K Warncke, J Reiter, A J K Williams, A G Ziegler, P J Bingley, E Bonifacio.   

Abstract

AIMS/HYPOTHESIS: Combinations of autoantibody characteristics, including antibody number, titre, subclass and epitope have been shown to stratify type 1 diabetes risk in islet autoantibody-positive relatives. The aim of this study was to determine whether autoantibody characteristics change over time, the nature of such changes, and their implications for the development of diabetes.
METHODS: Five-hundred and thirteen follow-up samples from 141 islet autoantibody-positive first-degree relatives were tested for islet autoantibody titre, IgG subclass, and GAD and IA-2 antibody epitope. All samples were categorised according to four risk stratification models. Relatives had a median follow-up of 6.8 years and 48 developed diabetes during follow-up. Survival analysis was used to determine the probability of change in risk category and of progression to diabetes.
RESULTS: For each stratification model, the majority of relatives (71-81%) remained in the same risk category throughout follow-up. In the remainder, changes occurred both from lower to higher and from higher to lower risk categories. For all four models, relatives aged < 15 years were more likely to change risk category than those aged >15 years (0.001 < p < 0.03). Relatives whose autoantibody status changed from low- to high-risk categories had a higher risk of diabetes than relatives who remained in low-risk categories, and inclusion of autoantibody status during follow-up improved diabetes risk stratification in Cox proportional hazards models (p < 0.001). CONCLUSIONS/
INTERPRETATION: Changes in islet autoantibodies are relevant to pathogenesis, and are likely to signal alterations in the disease process. Detection of changes through follow-up measurement will improve diabetes risk stratification, particularly in young individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17019596     DOI: 10.1007/s00125-006-0451-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation.

Authors:  E Bonifacio; M Scirpoli; K Kredel; M Füchtenbusch; A G Ziegler
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

2.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.

Authors:  Sefina Arif; Timothy I Tree; Thomas P Astill; Jennifer M Tremble; Amanda J Bishop; Colin M Dayan; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.

Authors:  J Dittler; D Seidel; M Schenker; A G Ziegler
Journal:  Diabetes       Date:  1998-04       Impact factor: 9.461

Review 4.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

5.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

6.  Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.

Authors:  C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

7.  Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents.

Authors:  Michael Hummel; Ezio Bonifacio; Sandra Schmid; Markus Walter; Annette Knopff; Anette-G Ziegler
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

8.  Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes.

Authors:  Jeffrey P Krischer; David D Cuthbertson; Liping Yu; Tihamer Orban; Noel Maclaren; Richard Jackson; William E Winter; Desmond A Schatz; Jerry P Palmer; George S Eisenbarth
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

9.  Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.

Authors:  Peter Achenbach; Katharina Warncke; Jürgen Reiter; Heike E Naserke; Alistair J K Williams; Polly J Bingley; Ezio Bonifacio; Anette-G Ziegler
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

10.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.

Authors:  E Bonifacio; P J Bingley; M Shattock; B M Dean; D Dunger; E A Gale; G F Bottazzo
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

View more
  12 in total

1.  Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes.

Authors:  A-G Ziegler; E Bonifacio
Journal:  Diabetologia       Date:  2012-07       Impact factor: 10.122

2.  A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children.

Authors:  David Endesfelder; Michael Hagen; Christiane Winkler; Florian Haupt; Stephanie Zillmer; Annette Knopff; Ezio Bonifacio; Anette-G Ziegler; Wolfgang Zu Castell; Peter Achenbach
Journal:  Diabetologia       Date:  2016-07-11       Impact factor: 10.122

Review 3.  Immunologic endocrine disorders.

Authors:  Aaron W Michels; George S Eisenbarth
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

4.  An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.

Authors:  I Vermeulen; I Weets; O Costa; M Asanghanwa; K Verhaeghen; K Decochez; J Ruige; K Casteels; J Wenzlau; J C Hutton; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

Review 5.  Prediction and pathogenesis in type 1 diabetes.

Authors:  Anette-G Ziegler; Gerald T Nepom
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

6.  Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.

Authors:  Marian Rewers; Peter Gottlieb
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

Review 7.  Insulin as an autoantigen in NOD/human diabetes.

Authors:  Li Zhang; Maki Nakayama; George S Eisenbarth
Journal:  Curr Opin Immunol       Date:  2008-02       Impact factor: 7.486

8.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

Authors:  Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

9.  Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.

Authors:  J M Barker; K K McFann; T Orban
Journal:  Diabetologia       Date:  2007-06-22       Impact factor: 10.122

10.  Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes.

Authors:  I Truyen; J De Grijse; I Weets; L Kaufman; L Pipeleers; N Nanos; K Decochez; R Hilbrands; J-M Kaufman; B Keymeulen; C Mathieu; L Van Gaal; D G Pipeleers; F K Gorus
Journal:  Clin Exp Immunol       Date:  2007-05-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.